Detailed Coverage

Link Pharma Chem Posts FY26 Profitability Turnaround

₹0.08 crore net profit in FY26 vs ₹1.03 crore loss in FY25. Revenue grew 7.86% to ₹27.43 crore.

Reader Takeaway: Profitability returns with revenue growth, but rising tax litigation and operational risks need monitoring.

What just happened

Link Pharma Chem Ltd announced its financial results for the fiscal year ended March 31, 2026. The company achieved a net profit of ₹0.08 crore (₹7.69 lakh), a significant turnaround from a net loss of ₹1.03 crore (₹102.73 lakh) in the previous fiscal year.

Revenue from operations saw a year-on-year increase of 7.86%, reaching ₹27.43 crore (₹2743.15 lakh) in FY 2025-26, compared to ₹25.43 crore in FY 2024-25.

The board also approved the re-appointment of Mr. Satish G. Thakur as Chairman & Whole-time Director and Mr. Rishikesh Thakur as Managing Director for new three-year terms, effective from mid-2026.

Why this matters

The return to profitability is a key positive signal for investors, indicating improved operational performance and cost management. The consistent revenue growth suggests sustained demand for the company's products. Re-appointment of key leadership provides stability and continuity in strategy.

However, a substantial increase in GST-related litigation, now standing at ₹1.55 crore as a contingent liability, presents a significant watch point. Additionally, auditors have flagged the need for enhanced inventory record audit trails.

The backstory

Link Pharma Chem operates in the chemical sector, manufacturing intermediates. The company has been working to navigate a challenging financial period, marked by losses in the previous fiscal year.

What changes now

With the return to profit, the company aims to build on this momentum. Investors will be looking for sustained profitability and growth. The management's focus will likely be on mitigating the risks identified, particularly the increasing tax liabilities.

Risks to watch

The primary risks highlighted are the escalating GST litigation, which could lead to significant financial outflows. Volatile raw material prices, influenced by geopolitical factors, pose a threat to future profit margins. Audit compliance regarding inventory records also needs attention.

Peer comparison

While specific peer financial data for the period isn't provided in the filing, the chemical industry often faces margin pressures from raw material costs and regulatory compliance. Companies in this sector typically focus on R&D to improve yields and product quality.

Context metrics (time-bound)

As of March 31, 2026, indirect tax litigation under the GST Act stood at ₹1.55 crore (₹154.59 lakh), a sharp rise from ₹0.08 crore (₹8.35 lakh) in the previous year. EPS for FY 2025-26 was ₹0.17, compared to a negative EPS of ₹2.31 in FY 2024-25.

What to track next

Investors should monitor the company's progress in resolving the GST litigation and any further impact on its financials. Tracking R&D initiatives for yield improvement and cost control in the face of raw material volatility will also be crucial.